Scientists find big challenges in accessing clinical trial data for FDA-approved cancer drugs

Credit: Unsplash+.

A recent study by an international team of scientists, including researchers from Flinders University and the University of Sharjah, highlights significant hurdles in accessing clinical trial data used for FDA-approved anticancer medicines.

Published in JAMA Oncology, their work underlines the importance of transparency in healthcare and the pharmaceutical industry.

Data Access: Successes and Struggles

The team initially requested data from 91 FDA-approved clinical trials and received data from 70, marking a 77% success rate. While this indicates progress in data sharing, the researchers encountered several challenges.

Dr. Ahmad Abuhelwa, a senior co-author, notes that 23% of trials denied access for various reasons. These included ongoing regulatory activities and concerns about proposed analyses.

This suggests significant barriers still exist in accessing clinical trial data, even when they are deemed eligible for sharing.

Issues with Transparency and Redactions

The researchers faced numerous issues, including lengthy access times (up to one year) and redactions in key data areas such as adverse events and survival rates.

Such redactions can hinder the analysis and usability of data. Additionally, many trials lacked essential supporting documents like clinical study reports and data dictionaries, which are crucial for understanding and validating the data.

The study also revealed a lack of standardization in how different companies provide their data, leading to heterogeneity and complicating the research process.

Dr. Ashley Hopkins, the study’s lead author, emphasizes the need for comprehensive and unredacted data access, highlighting the importance of standardization in data sharing practices.

Implications and Recommendations

This research is a call to action for the pharmaceutical industry to improve data accessibility and quality. The scientists recommend providing full access to complete and unredacted data, emphasizing transparency and standardization.

Such improvements are crucial for advancing healthcare research and improving patient outcomes.

The Path Forward

Dr. Abuhelwa views the study as a roadmap for what the pharmaceutical industry needs to do to share clinical trial data effectively. The goal is to create a data-sharing ecosystem where accessibility and quality are paramount.

Dr. Hopkins hopes the industry will take note of these findings, as standardized data sharing practices are vital for empowering researchers and healthcare providers.

In summary, this study sheds light on the progress and ongoing challenges in sharing clinical trial data in the pharmaceutical industry.

It underscores the need for increased transparency, standardization, and accessibility to improve healthcare research and patient care.

If you care about cancer, please read studies about A common blood thinner can help fight cancer and findings of Heavy alcohol drinking is common in cancer patients.

For more information about health, please see recent studies about how drinking milk affects risks of heart disease and cancer, and results showing DASH diet is good for your blood pressure, and vegetable diet may reduce heart disease risk.

The research findings can be found in JAMA Oncology.

Copyright © 2023 Knowridge Science Report. All rights reserved.